Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

As the first FDA-approved treatment for Alzheimer agitation, brexpiprazole showcased effective symptom relief with a favorable safety profile.

Post Hoc Analysis Highlights Brexpiprazole’s Efficacy and Tolerability in Alzheimer Agitation

Videos

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai explained how his team validated an iRBD actigraphy classifier across new devices and datasets to enhance early, scalable screening for neurodegenerative disease. [WATCH TIME: 5 minutes]

Validating a Wearable-Based Classifier to Detect iRBD: Emmanuel During, MD

New findings reveal deramiocel's promising long-term benefits for boys with Duchenne muscular dystrophy cardiomyopathy, enhancing cardiac function and muscle performance.

Long-Term 4-Year Data Highlights Sustained Effects of Deramiocel in DMD Cardiomyopathy

The sleep and stroke neurologist at Barrow Neurological Institute provided insights on the potential of sleep-boosting strategies—including pharmacologic options—to enhance glymphatic clearance and improve stroke recovery outcomes. [WATCH TIME: 4 minutes]

Targeting Sleep and the Glymphatic Pathway to Improve Stroke Rehabilitation Outcomes: Joyce Lee-Iannotti, MD, FAAN, FAASM

, has been with the team since September 2022. Follow her on Twitter 

A physician assistant specializing in Parkinson disease shared key clinical considerations for selecting and educating patients about on-demand therapies for the movement disorder.

NeuroVoices: Cheryl Kyinn, PA-C, on Personalizing On-Demand Therapies for OFF Episodes in Parkinson Disease

At ATMRD 2025, a patient advocate living with PD and advisory board member of the Parkinson's Foundation outlined key nonpharmacologic tools that have supported her care journey. [WATCH TIME: 5 minutes]

Sharing Treatment Strategies for Patients With Parkinson Disease Beyond Medication: Esther Labib-Kiyarash, MSHA, CPHQ

The neurologist at Christiana Care discussed how focused ultrasound may be emerging as a preferred, less invasive treatment option for essential tremor, especially in older patients with comorbidities. [WATCH TIME: 5 minutes]

Increased Awareness for Essential Tremor Treatment, MR-guided Focused Ultrasound: Justin Martello, MD

Director, Movements Disorders Clinic, Houston Methodist Neurological Institute; and professor of neurology, Weill Cornell Medical College

The director of the Movement Disorders Clinic at Houston Methodist Hospital discussed the distinct features, progression, and clinical implications of psychosis in Parkinson disease. [WATCH TIME: 4 minutes]

Understanding the Phenomenology and Impact of Psychosis in Parkinson Disease: William Ondo, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Slideshows

Migraine is the second leading cause of disability worldwide. New data show the number of patients who will need care by clinicians with expertise in neurological conditions will continue to grow in coming decades.

Clinical

BIO-22-NRD0187 - /clinical/headache-migraine

Neurological Disorders and the Global Burden of Disease

Neurological Disorders and the Global Burden of Disease

Newsletter